Lv74
3300 积分 2024-02-08 加入
Survival of patients with marginal zone lymphoma
12天前
已关闭
The Treatment of Marginal Zone Lymphoma
13天前
已完结
Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology Guideline
1个月前
已完结
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges
3个月前
已完结
Advances in Primary Central Nervous System Lymphoma
3个月前
已完结
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
5个月前
已完结
Primary Large B-cell Lymphomas of Immune-Privileged Sites
7个月前
已完结
Primary Large B-cell Lymphomas of Immune-Privileged Sites
7个月前
已关闭
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
7个月前
已完结
The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096)
7个月前
已完结
皖公网安备34019202002308
